Filing Flows › Health Care › Connect Biopharma Holdings (CNTB)
Connect Biopharma Holdings (CNTB) earnings and revenue breakdown
Latest: Q2 2026 · 10-Q filed Aug 12, 2026 · Connect Biopharma Holdings (CNTB) Q2 2026 earnings results →
Q2 2026 Revenue up 5667% year over year to $2.8M · 624¢ of every $1 of revenue lost · operating margin -636.0%
Connect Biopharma Holdings made $2.8M in Q2 2026 (58× Y/Y). Operating margin -636.0%, net loss $17.3M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Aug 12, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $2.8M in Q2 2026, up 5667% year over year and up 1538% from the previous quarter.
Operating costs exceeded revenue by $17.6M, an operating margin of -636.0%. Total costs grew 51% against revenue growth of 5667%. The fastest-growing cost line was Research & development (+85%). The quarter ended with a net loss of $17.3M, narrower than the previous quarter's $19.4M loss.
Operating cash flow was −$15.9M. Non-cash charges added back $161K of depreciation and amortization and $1.3M of share-based compensation.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 10-Q | Aug 12, 2026 | $2.8M | 58× | -636.0% | −$17.3M | −$15.9M |
| Q1 2026 | 10-Q | May 12, 2026 | $169K | — | n/m | −$19.4M | −$16.0M |
| Q3 2025 | 10-Q | Nov 12, 2025 | $16K | -99% | n/m | −$17.2M | −$17.4M |
| Q2 2025 | 10-Q | Aug 13, 2025 | $48K | -100% | n/m | −$12.9M | −$12.6M |
| Q4 2024 | 10-K | Mar 31, 2025 | $698K | — | n/m | −$8.9M | −$2.3M |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
About Connect Biopharma Holdings
Connect Biopharma, headquartered in San Diego, California, is a clinical-stage biopharmaceutical company dedicated to transforming care for asthma and chronic obstructive pulmonary disease (“COPD”). The Company is advancing rademikibart, a next-generation, potentially best-in-class antibody designed to target interleukin-4-receptor alpha (“IL-4Rα”). Asthma is a chronic inflammatory disease that affects the airways in the lungs and makes it difficult to breathe. It is one of the most common and costly diseases in the U.S., with an estimated 23 million adults and an estimated 5 million children suffering from asthma. Globally, asthma affected an estimated 262 million people in 2019 and caused 455,000 deaths. Asthma is associated with severe exacerbations that are difficult to treat and often require hospitalization.
In its own words, from its 10-K, filed Mar 31, 2026.
Connect Biopharma Holdings against its Pharmaceutical Preparations peers
The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: 58× against the peers' median +10%. Operating margin: -636.0% against the peers' median 20.4%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| CNTB Connect Biopharma Holdings | Q2 2026 | $2.8M | 58× | -636.0% |
| JNJ Johnson & Johnson | Q3 2026 | $25.4B | +6% | 0.1% |
| LLY ELI Lilly | Q3 2026 | $24.4B | +39% | 34.5% |
| MRK Merck | Q3 2026 | $18.1B | +5% | 30.7% |
| ABBV AbbVie | Q3 2026 | $17.4B | +10% | 36.0% |
| PFE Pfizer | Q3 2026 | $16.6B | -0.4% | 20.4% |
| BMY Bristol Myers Squibb | Q3 2026 | $13.1B | +7% | 19.4% |
| ABT Abbott Laboratories | Q3 2026 | $13.0B | +14% | 10.4% |
| REGN Regeneron Pharmaceuticals | Q3 2026 | $5.1B | +36% | 40.0% |
Source: Connect Biopharma Holdings 10-Q on SEC EDGAR · CIK 1835268 · Pharmaceutical Preparations
More on CNTB
History
Every quarter: Q2 2026 results · Q1 2026 results · Q3 2025 results · Q2 2025 results · Q4 2024 results
Compare CNTB with
- Connect Biopharma Holdings vs Atrium Therapeutics (CNTB vs RNA)
- Connect Biopharma Holdings vs CV Sciences (CNTB vs CVSI)
- Connect Biopharma Holdings vs Traws Pharma (CNTB vs TRAW)
- Connect Biopharma Holdings vs International Stem Cell (CNTB vs ISCO)
- Connect Biopharma Holdings vs Evofem Biosciences (CNTB vs EVFM)